Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

The medical device maker reported another solid quarter.

Why Intuitive Surgical Keeps Growing and Growing

Intuitive Surgical reported its Q4 results last week, with revenue above, but earnings falling short of our estimates. The company reported revenue of $1.55 billion (up 17% y-o-y), marginally above our forecast of $1.53 billion and the consensus estimate of $1.52 billion.

Intuitive Surgical Stock Looks Attractive After Its Recent Fall

Bath and Body Works

Netflix

Investors looking to buy the dip should consider companies that have been hit hardest but still have solid long-term growth prospects. It is here that valuations have become more reasonable and entry points more attractive.

3 S&P 500 Laggards To Buy On the Dip

Berkshire Grey

Luminar Technologies

Ouster, Inc

Vicarious Surgical

Titan Medical Inc

Trimble

Velodyne Lidar

Zebra Technologies

December 2021 saw investments in robotics of roughly USD1.2bn. The lion's share of the funding in went to autonomous driving companies.

Robotics Investments In December 2021

Surgical robotics is increasingly being adopted by doctors and patients, and the market is expected to rapidly expand by 19.3% over the next several years. ISRG is extremely profitable, with profit margins around 70%, and a cash balance that has increased $1.7 B over fiscal 2021.

Intuitive Surgical: Market Leader In Robotic Surgery

It wasn't all about the streaming company.

These 2 Nasdaq Stocks Are Falling Despite Better Results Than Netflix

This isn't how earnings beats are supposed to work.

Why Intuitive Surgical Stock Just Dropped

Intuitive Surgical's (ISRG) fourth-quarter results reflect strong segmental performance.

Intuitive Surgical (ISRG) Q4 Earnings & Revenues Top Estimates

A Citigroup analyst believes the pullback in shares of Intuitive Surgical is a buying opportunity.

Intuitive Surgical Stock Falls After Earnings. This Analyst Thinks It's a Buy.

Intuitive Surgical Inc (NASDAQ: ISRG) reported Q4 adjusted EPS of $1.30, slightly ahead of the consensus of $1.28. It reported revenues of $1.55 billion, +17% Y/Y, marginally ahead of Wall Street estimate of $1.52 billion, consistent with the preliminary results posted earlier this month.

Intuitive Surgical Q4 Earnings Beat Street, Expects Lower Gross Margin In FY22

The surgical robotics leader produces tremendous results, but the pandemic has been a persistent headwind over the past two years.

3 Reasons to Buy Intuitive Surgical, and 1 Reason to Sell

Intuitive Surgical, Inc. (ISRG) CEO Gary Guthart on Q4 2021 Results - Earning Call Transcript

Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 1.56% and 0.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Beats Q4 Earnings and Revenue Estimates

Shares of Intuitive Surgical Inc. ISRG, -0.25% fell more than 4% in the extended session Thursday after the health care company reported fourth-quarter earnings and sales slightly above expectations but said the pandemic continues to lead to fewer procedures done with its main robotic surgical system. Intuitive said it earned $381 million, or $1.04 a share, in the quarter, compared with $365 million, or $1.01 a share, in the fourth quarter of 2020.

Intuitive Surgical stock falls after company earnings hurt by fewer procedures

The biggest questions relate to how it's faring amid the omicron variant's disruption.

Here's What Investors Should Look for in Intuitive Surgical's Earnings Report

With the rise of the Omicron and Covid-19 cases in the U.S. since December, it is likely that Intuitive Surgical's sales in certain geographies were adversely impacted.

What To Expect From Intuitive Surgical's Q4?

Fastenal

PPG Industries

United Continental Hlds

Union Pacific

Earnings season heats up this week with large cap stalwarts ready to set the tone.

5 Must-See Large Cap Earnings Charts

Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance at the Instruments & Accessories segment.

What's in Store for Intuitive Surgical's (ISRG) Q4 Earnings?

Intuitive Surgical (ISRG) posts solid fourth-quarter and full-year 2021 results driven primarily by da Vinci procedure volume growth.

Intuitive Surgical (ISRG) Posts Robust Preliminary Q4 Results

Intuitive Surgical, Inc. (ISRG) closed at $307.74 in the latest trading session, marking a -1.75% move from the prior day.

Intuitive Surgical, Inc. (ISRG) Stock Sinks As Market Gains: What You Should Know

Intuitive Surgical, Inc. (ISRG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Intuitive Surgical, Inc. (ISRG) Loses 6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Last month we discussed that the stock price of Intuitive Surgical is likely to see higher levels based on the stock's historical performance, but it appeared to have limited upside. ISRG stock rose from levels of around $340 on Dec 9, 2021 to $360 earlier this month, before cooling off to levels.

What's Happening With Intuitive Surgical Stock?

Intuitive Surgical, Inc. (ISRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intuitive Surgical, Inc. (ISRG) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Intuitive Surgical, Inc. (ISRG) CEO Gary Guthart Presents at JPMorgan 40th Annual Healthcare Conference (Transcript)

Intuitive Surgical Inc (NASDAQ: ISRG) posted interim Q4 sales of $1.55 billion, +17% Y/Y, better than the consensus of $1.51 billion. Preliminary 2021 revenue of approximately $5.71 billion increased 31% Y/Y, ahead of analysts' estimate of $5.68 billion.

News for Intuitive Surgical Stock (ISRG)